Online inquiry

IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11231MR)

This product GTTS-WQ11231MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets pcrV&psl gene. The antibody can be applied in P. Aeruginosa nosocomial pneumonia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11231MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9648MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ915MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ1268MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ2330MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ27MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ4813MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ7667MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ9197MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN853
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW